Johnson & Johnson (LTS:0R34) 3-Year EPS without NRI Growth Rate : 21.10% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Johnson & Johnson 3-Year EPS without NRI Growth Rate?

Johnson & Johnson's EPS without NRI for the three months ended in Dec. 2023 was $2.29.

During the past 12 months, Johnson & Johnson's average EPS without NRI Growth Rate was 36.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 21.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Johnson & Johnson was 107.40% per year. The lowest was -52.20% per year. And the median was 12.50% per year.

Competitive Comparison of Johnson & Johnson's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Johnson & Johnson's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Johnson & Johnson's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's 3-Year EPS without NRI Growth Rate falls into.

Johnson & Johnson 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Johnson & Johnson (LTS:0R34) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Johnson & Johnson 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson (LTS:0R34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (LTS:0R34) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

JNJ:USA JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson (LTS:0R34) Headlines

No Headlines